Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815853 | 0.90 | CASP2 (0.56) | CASP2NAAAACHEFAAHGLP1R | |
| SCHEMBL19477862 | 0.89 | CASP2 (0.58) | CASP2NAAAFAAHTSHRCNR1 | |
| SCHEMBL8251628 | 0.89 | CASP2 (0.63) | CASP2NAAAACHEFAAHCNR1 | |
| SCHEMBL10048529 | 0.89 | CASP2 (0.55) | CASP2NAAAFAAHTSHRCNR1 | |
| SCHEMBL25678313 | 0.88 | CASP2 (0.49) | CASP2NAAAACHEFAAHGLP1R | |
| SCHEMBL19662065 | 0.88 | CASP2 (0.47) | CASP2FAAHGLP1RTSHRCNR1 | |
| SCHEMBL27410517 | 0.88 | CASP2 (0.52) | CASP2NAAAACHEFAAHTSHR | |
| SCHEMBL27142733 | 0.88 | CASP2 (0.61) | CASP2NAAAFAAHGLP1RCNR1 | |
| SCHEMBL24341463 | 0.87 | CASP2 (0.55) | CASP2NAAAACHEFAAHTSHR | |
| SCHEMBL11912076 | 0.87 | CASP2 (0.66) | CASP2NAAAFAAHTSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CASP2 578/4885NAAA 179/4885ACHE 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.